Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022.

IF 7.5 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Chinese Medical Journal Pub Date : 2024-10-20 Epub Date: 2024-09-05 DOI:10.1097/CM9.0000000000003278

Kexin Sun, Bailin Zhang, Shaoyuan Lei, Rongshou Zheng, Xin Liang, Li Li, Xiaolong Feng, Siwei Zhang, Hongmei Zeng, Yifei Yao, Peiqing Ma, Shaoming Wang, Ru Chen, Bingfeng Han, Wenqiang Wei, Jie He

{"title":"Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022.","authors":"Kexin Sun, Bailin Zhang, Shaoyuan Lei, Rongshou Zheng, Xin Liang, Li Li, Xiaolong Feng, Siwei Zhang, Hongmei Zeng, Yifei Yao, Peiqing Ma, Shaoming Wang, Ru Chen, Bingfeng Han, Wenqiang Wei, Jie He","doi":"10.1097/CM9.0000000000003278","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.Methods: In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).Results: In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.Conclusion: These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2429-2436"},"PeriodicalIF":7.5000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479498/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CM9.0000000000003278","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.

Methods: In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).

Results: In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.

Conclusion: These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.

查看原文本刊更多论文

2022 年中国女性乳腺癌的发病率、死亡率和残疾调整生命年。

背景乳腺癌是中国女性人口中发病率最高的恶性肿瘤之一。然而，详细记录最新流行病学数据和可归因疾病负担的综合报告并不广泛：2018 年，中国 700 个基于人群的癌症登记处记录了高质量的癌症监测数据。我们提取了女性乳腺癌（国际疾病分类第十版 [ICD-10]：C50）的数据，并根据基线数据和 2010 年至 2018 年的相应趋势估算了 2022 年的发病率和死亡率。病理类型根据《国际肿瘤疾病分类》第三版代码进行分类。残疾调整生命年（DALYs）的计算方法是损失生命年（YLLs）和残疾生活年（YLDs）之和：2022年，中国女性乳腺癌新发病例约为35.72万例，死亡病例约为7.5万例，分别占癌症新发病例和死亡病例总数的15.59%和7.94%。年龄标准化发病率（ASIR）为33.04/10万。按病理类型分析，乳头状瘤、浸润性乳腺癌、罕见和唾液腺型肿瘤以及其他类型的年龄标准化发病率分别为每 10 万人 1.13 例、29.79 例、0.24 例和 1.88 例。年龄标准化死亡率（ASMR）为每 10 万人 6.10 例。中国女性乳腺癌导致的残疾调整寿命年数为262.8万年，包括227.83万年残疾调整寿命年数和34.97万年残疾调整寿命年数。城市地区的DALYs ASIR、ASMR和年龄标准化率（ASR）一直高于农村地区。我们观察到，与 55 岁以下女性相比，55 岁以上女性的 DALYs ASIR 和 ASR 增加了四倍，ASMR 增加了八倍：这些数据为了解中国女性乳腺癌的最新流行病学情况提供了宝贵的信息，并凸显了制定疾病预防和控制策略的紧迫性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Medical Journal 医学-医学：内科

CiteScore

9.80

自引率

4.90%

发文量

19245

审稿时长

6 months

期刊介绍： The Chinese Medical Journal (CMJ) is published semimonthly in English by the Chinese Medical Association, and is a peer reviewed general medical journal for all doctors, researchers, and health workers regardless of their medical specialty or type of employment. Established in 1887, it is the oldest medical periodical in China and is distributed worldwide. The journal functions as a window into China’s medical sciences and reflects the advances and progress in China’s medical sciences and technology. It serves the objective of international academic exchange. The journal includes Original Articles, Editorial, Review Articles, Medical Progress, Brief Reports, Case Reports, Viewpoint, Clinical Exchange, Letter,and News,etc. CMJ is abstracted or indexed in many databases including Biological Abstracts, Chemical Abstracts, Index Medicus/Medline, Science Citation Index (SCI), Current Contents, Cancerlit, Health Plan & Administration, Embase, Social Scisearch, Aidsline, Toxline, Biocommercial Abstracts, Arts and Humanities Search, Nuclear Science Abstracts, Water Resources Abstracts, Cab Abstracts, Occupation Safety & Health, etc. In 2007, the impact factor of the journal by SCI is 0.636, and the total citation is 2315.